Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from ZYUS Life Sciences ( (TSE:ZYUS) ) is now available.
ZYUS Life Sciences reported favourable preliminary data from its ongoing Phase 2a UTOPIA-1 trial of Trichomylin softgel capsules in patients with advanced cancer experiencing moderate to severe pain. Early results from the first cohort of patients indicate reductions in average daily pain, pain interference and severity, along with lower opioid use for breakthrough pain, and no serious adverse events related to the drug, suggesting it is generally well tolerated. Management framed the data as an important proof-of-concept milestone that validates the trial design and supports the potential progression of Trichomylin into later-stage studies as a non-opioid alternative for cancer-related pain, underscoring the company’s long-term investment in developing differentiated pain therapies.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences is a clinical-stage life sciences company specializing in the development and commercialization of novel cannabinoid-based, non-opioid pharmaceutical drug candidates for pain management, with a particular focus on securing intellectual property and regulatory approvals to support its position in the emerging non-opioid pain treatment market.
Average Trading Volume: 6,061
Technical Sentiment Signal: Sell
Current Market Cap: C$54.45M
For detailed information about ZYUS stock, go to TipRanks’ Stock Analysis page.